• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    12/13/21 4:15:45 PM ET
    $THMA
    Finance
    Get the next $THMA alert in real time by email
    SC 13G 1 tm2135160d1_sc13g.htm SCHEDULE 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Pear Therapeutics, Inc.

    (Name of Issuer)

     

    Class A Common stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    704723105

    (CUSIP Number)

     

    December 3, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 704723105

     

      1.

    Names of Reporting Persons

    Arboretum Ventures IV, L.P.

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization

    Delaware

         

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

     
    6.

    Shared Voting Power

    10,859,050 shares (2)

     
    7.

    Sole Dispositive Power

    0

     
    8.

    Shared Dispositive Power

    10,859,050 shares (2)

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    10,859,050 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11.

    Percent of Class Represented by Amount in Row (9)

    7.9% (3)

     
      12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1)This Schedule 13G is filed by Arboretum Ventures IV, L.P. (“Arboretum IV LP”), Arboretum Investment Manager IV, LLC (“Arboretum IV GP”), Jan L. Garfinkle (“Garfinkle”), Paul McCreadie (“McCreadie”) and Timothy B. Petersen (“Petersen” and together with Arboretum IV LP, Arboretum IV GP, Garfinkle and McCreadie, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Arboretum IV LP. Arboretum IV GP serves as the sole general partner of Arboretum IV LP and owns no securities of the Issuer directly. Garfinkle, McCreadie and Petersen are managing directors of IV LLC and share voting and dispositive power over the shares held by Arboretum IV LP.
    (3)This calculation is based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021 as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021.

     

    2

     

     

    CUSIP No. 704723105

     

      1.

    Names of Reporting Persons

    Arboretum Investment Manager IV, LLC

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization

    Delaware

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

     
    6.

    Shared Voting Power

    10,859,050 shares (2)

     
    7.

    Sole Dispositive Power

    0

     
    8.

    Shared Dispositive Power

    10,859,050 shares (2)

     
      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    10,859,050 shares (2)

     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11.

    Percent of Class Represented by Amount in Row (9)

    7.9% (3)

     
      12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Arboretum IV LP. Arboretum IV GP serves as the sole general partner of Arboretum IV LP and owns no securities of the Issuer directly. Garfinkle, McCreadie and Petersen are managing directors of IV LLC and share voting and dispositive power over the shares held by Arboretum IV LP.
    (3)This calculation is based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021 as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021.

     

    3

     

     

    CUSIP No. 704723105

     

      1.

    Names of Reporting Persons

    Jan L. Garfinkle

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization

    United States of America

         

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

     
    6.

    Shared Voting Power

    10,859,050 shares (2)

     
    7.

    Sole Dispositive Power

    0

     
    8.

    Shared Dispositive Power

    10,859,050 shares (2)

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    10,859,050 shares (2)

     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11.

    Percent of Class Represented by Amount in Row (9)

    7.9% (3)

     
      12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Arboretum IV LP. Arboretum IV GP serves as the sole general partner of Arboretum IV LP and owns no securities of the Issuer directly. Garfinkle, McCreadie and Petersen are managing directors of IV LLC and share voting and dispositive power over the shares held by Arboretum IV LP.
    (3)This calculation is based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021 as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021.

     

    4

     

     

    CUSIP No. 704723105

     

      1.

    Names of Reporting Persons

    Paul McCreadie

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization

    United States of America

         

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

     
    6.

    Shared Voting Power

    10,859,050 shares (2)

     
    7.

    Sole Dispositive Power

    0

     
    8.

    Shared Dispositive Power

    10,859,050 shares (2)

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    10,859,050 shares (2)

     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11.

    Percent of Class Represented by Amount in Row (9)

    7.9% (3)

     
      12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Arboretum IV LP. Arboretum IV GP serves as the sole general partner of Arboretum IV LP and owns no securities of the Issuer directly. Garfinkle, McCreadie and Petersen are managing directors of IV LLC and share voting and dispositive power over the shares held by Arboretum IV LP.
    (3)This calculation is based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021 as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021.

     

    5

     

     

    CUSIP No. 704723105

     

      1.

    Names of Reporting Persons

    Timothy B. Petersen

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization

    United States of America

         

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

     
    6.

    Shared Voting Power

    10,859,050 shares (2)

     
    7.

    Sole Dispositive Power

    0

     
    8.

    Shared Dispositive Power

    10,859,050 shares (2)

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    10,859,050 shares (2)

     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11.

    Percent of Class Represented by Amount in Row (9)

    7.9% (3)

     
      12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Arboretum IV LP. Arboretum IV GP serves as the sole general partner of Arboretum IV LP and owns no securities of the Issuer directly. Garfinkle, McCreadie and Petersen are managing directors of IV LLC and share voting and dispositive power over the shares held by Arboretum IV LP.
    (3)This calculation is based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021 as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021.

     

    6

     

     

     

    Item 1.
      (a)

    Name of Issuer

     

    Pear Therapeutics, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

     

    200 State Street, 13th Floor, Boston, Massachusetts 02109

    Item 2.
      (a)

    Name of Person Filing

     

    Arboretum Ventures IV, L.P. (“Arboretum IV LP”)

    Arboretum Investment Manager IV, LLC (“Arboretum IV GP”)

    Jan L. Garfinkle (“Garfinkle”)

    Paul McCreadie (“McCreadie”)

    Timothy B. Petersen (“Petersen”)

      (b)

    Address of Principal Business Office or, if none, Residence

     

    c/o Arboretum Ventures

    Market Place Building

    303 Detroit Street, Suite 301

    Ann Arbor, MI 48104

      (c)

    Citizenship

     

    Entities:

     

     

     

     

    Arboretum IV LP      -     Delaware, United States of America

    Arboretum IV GP      -     Delaware, United States of America

     

       

    Individuals:

     

     

    Garfinkle        -            United States of America
    McCreadie      -            United States of America
    Petersen          -            United States of America
      (d)

    Title of Class of Securities

     

    Class A Common Stock, $0.0001 par value (“Common Stock”)

      (e)

    CUSIP Number

     

    704723105

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable

     

    7

     

     

    Item 4.Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    Reporting Persons 

    Shares Held

    Directly

      

    Sole

    Voting

    Power

      

    Shared

    Voting

    Power

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power

      

    Beneficial

    Ownership

      

    Percentage

    of Class (2)

     
    Arboretum IV LP   10,859,050    0    10,859,050    0    10,859,050    10,859,050    7.9%
    Arboretum IV GP (1)   0    0    10,859,050    0    10,859,050    10,859,050    7.9%
    Garfinkle (1)   0    0    10,859,050    0    10,859,050    10,859,050    7.9%
    McCreadie (1)   0    0    10,859,050    0    10,859,050    10,859,050    7.9%
    Petersen (1)   0    0    10,859,050    0    10,859,050    10,859,050    7.9%

     

    (1)   These shares are held by Arboretum IV LP. Arboretum IV GP serves as the sole general partner of Arboretum IV LP and owns no securities of the Issuer directly. Garfinkle, McCreadie and Petersen are managing directors of IV LLC and share voting and dispositive power over the shares held by Arboretum IV LP.

     

    (2)   This calculation is based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021 as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021. 

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable

     

    Item 9. Notice of Dissolution of Group
       
      Not applicable

     

    Item 10. Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    8

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 13, 2021

     

    Arboretum Ventures IV, L.P.

     

    By: Arboretum Investment Manager IV, LLC    
    its General Partner  

     

    By: /s/ Jan L. Garfinkle  
      Name: Jan L. Garfinkle  
      Title: Managing Director  

     

    Arboretum Investment Manager IV, LLC

     

    By: /s/ Jan L. Garfinkle  
      Name: Jan L. Garfinkle  
      Title: Managing Director  

     

    /s/ Jan L. Garfinkle  
    Jan L. Garfinkle  

     

    /s/ Paul McCreadie  
    Paul McCreadie  

     

    /s/ Timothy B. Petersen  
    Timothy B. Petersen  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    9

     

     

    Exhibit(s):

     

    A - Joint Filing Statement

     

    10

     

     

    EXHIBIT A

     

    JOINT FILING STATEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Pear Therapeutics, Inc. is filed on behalf of each of us.

     

    Dated: December 13, 2021

     

    Arboretum Ventures IV, L.P.

     

    By: Arboretum Investment Manager IV, LLC    
    its General Partner  

     

    By: /s/ Jan L. Garfinkle  
      Name: Jan L. Garfinkle  
      Title: Managing Director  

     

    Arboretum Investment Manager IV, LLC

     

    By: /s/ Jan L. Garfinkle  
      Name: Jan L. Garfinkle  
      Title: Managing Director  

     

    /s/ Jan L. Garfinkle  
    Jan L. Garfinkle  

     

    /s/ Paul McCreadie  
    Paul McCreadie  

     

    /s/ Timothy B. Petersen  
    Timothy B. Petersen  

     

     

     

    Get the next $THMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company

    Publicly traded company called Pear Therapeutics, Inc. to begin trading on Nasdaq under ticker symbol "PEAR" starting December 6, 2021 Total expected gross proceeds from transaction totaling approximately $175 million Pear Therapeutics, Inc. ("Pear Therapeutics"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced today the completion of its business combination with Thimble Point Acquisition Corp. ("Thimble Point") (NASDAQ:THMA), a special purpose acquisition company ("SPAC"). The publicly traded company will be known as Pear Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol "

    12/3/21 4:12:00 PM ET
    $THMA
    Finance

    Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET. A live audio webcast can be accessed by clicking here and will be made available on Pear's website at www.peartherapeutics.com. A replay will be available for approximately 30 days following the live presentation. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PD

    11/23/21 8:00:00 AM ET
    $THMA
    Finance

    Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD). reSET-A potentially expands Pear's addiction franchise, which includes FDA-authorized products to treat substance use disorder (SUD) and opioid use disorder (OUD). This is the second such Breakthrough Device Designation received by Pear, following the designation awarded for reSET-O®, the first ever for a PDT, which was for the treatment

    11/22/21 8:00:00 AM ET
    $THMA
    Finance

    $THMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider 5am Partners Iv, Llc claimed ownership of 18,631,771 shares

    3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/13/21 4:26:37 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Bauerlein Alison

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:47:18 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Reddy Kirthiga

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:46:17 PM ET
    $THMA
    Finance

    $THMA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Thimble Point Acquisition Corp.

    25-NSE - Thimble Point Acquisition Corp. (0001835567) (Subject)

    12/3/21 4:02:15 PM ET
    $THMA
    Finance

    SEC Form 425 filed by Thimble Point Acquisition Corp.

    425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

    11/30/21 4:42:53 PM ET
    $THMA
    Finance

    Thimble Point Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

    11/30/21 4:38:59 PM ET
    $THMA
    Finance

    $THMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:30:52 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:57 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:15 PM ET
    $THMA
    Finance